AZTRHealthcare · Biotechnology

AZTR Stock Forecast: Azitra, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$0.13

The 1 Wall Street analysts covering Azitra, Inc. hold a median 12-month price target of $0.78 — +483.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$2.2M

Ticker Nerd rank

28 / 100

Median analyst target

$0.78

Analysts covering

Ticker Nerd rank

AZTR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Azitra, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Revisions

Volatility

Growth

Issuance

Momentum

Quality

Value

Size (94): Smaller than most of the companies we track.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AZTR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AZTR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $0.55Median $0.78High $1.00

The green dot is the last close — the median target sits +483.6% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
24 Sept 2025	Maxim Group	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AZTR appears on the weeks it earns a place.

Estimates

AZTR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Azitra, Inc. (AZTR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 6.6×
Price / sales: —
Price / book: 1.1×
EV / EBITDA: −0.1×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −256.7%
Return on assets: −119.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AZTR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
AZTRAzitra, Inc.	$2.2M	28
TRAWTraws Pharma, Inc.	$8.0M	48
ERNAErnexa Therapeutics, Inc.	$7.9M	34
APREAprea Therapeutics, Inc.	$7.9M	44
XBIOXenetic Biosciences, Inc.	$8.2M	39
AIMAIM ImmunoTech, Inc.	$7.9M	20
ACXPAcurx Pharmaceuticals, Inc.	$7.7M	24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Azitra, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AZTR news & analysis

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

PRNewsWire · 21 Aug 2026positive

Azitra, Inc. announced it received written notification from NYSE American confirming that the company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.

Why it matters — Regaining compliance removes the risk of potential delisting from NYSE American, preserving Azitra's continued listing status on the exchange.

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates

PRNewsWire · 12 Aug 2026neutral

Azitra, Inc. reported its financial results for the quarter ended June 30, 2026, and provided a business update. The company, a clinical-stage biopharmaceutical firm focused on precision dermatology and high-value cosmetic proteins and peptides, announced these results on August 12, 2026.

Why it matters — Azitra watchers would care because the announcement covers the company's latest quarterly financial performance and operational progress for the dermatology-focused biopharmaceutical firm.

FAQ

Frequently asked questions about AZTR stock

What is the AZTR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Azitra, Inc. have a median 12-month price target of $0.78, with estimates ranging from $0.55 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AZTR stock a buy right now?

Of the 1 analysts covering Azitra, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Azitra, Inc. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AZTR?

As at 22 Aug 2026, Azitra, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will AZTR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +483.6% from the last close, and Ticker Nerd's factor model ranks Azitra, Inc. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AZTR stock forecast for 2030?

No analyst covering Azitra, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.55 to $1 over the next 12 months.

What does Azitra, Inc. do?

Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome.

What is the latest news on AZTR?

The most recent item we track (PRNewsWire, 21 Aug 2026): "Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards". Azitra, Inc. announced it received written notification from NYSE American confirming that the company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.

Company

About Azitra, Inc.

Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome. The company is dedicated to developing microbiome-based treatments to address dermatological conditions and improve skin health. Azitra leverages its proprietary platform to design therapies that utilize commensal microbiota, which are the naturally occurring bacteria on human skin, for combating various skin diseases. By targeting skin-associated microbiomes, Azitra aims to create safe and effective treatment options for conditions that may not respond well to conventional treatments. Its innovative approach positions Azitra in the emerging field of microbiome therapy, impacting healthcare and dermatology industries. With its specialized focus, Azitra plays a significant role in advancing biotechnology innovations and contributing to the evolving narrative of precision medicine and personalized healthcare.

CEO Mr. Francisco D. Salva · 13 employees · United States · https://azitrainc.com